Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiyanping injection plus conventional therapy for common COVID-19
ChiCTR2000030117Phase 4Recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Feb 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of andrographolide sulfonate in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: Clinical recovery time. Started Feb 2020; status: recruiting.
02
Drugs
andrographolide sulfonate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030117.